Navigation Links
ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease
Date:8/7/2008

KIRKLAND, Wash., Aug. 7 /PRNewswire/ -- ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the FDA to initiate its Phase 1 human clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. ProteoTech initiated its Phase 1 human trial on July 29, 2008.

At the 2008 International Conference on Alzheimer's disease in Chicago last week, ProteoTech presented remarkable efficacy data in Alzheimer's transgenic mice, whereby Exebryl-1(R) lowered brain beta-amyloid protein load by greater than 30-50%, correlating with marked improvements in memory in these animals. Toxic and insoluble beta-amyloid protein accumulation is believed to be an important part of the disease progression and memory impairment observed in all patients with Alzheimer's disease. Data was also presented demonstrating oral bioavailability and blood-brain-barrier penetration of Exebryl-1(R).

Exebryl-1(R) is a novel small molecule drug developed at ProteoTech from its unique library of small molecule compounds designed to target specific amyloid diseases. Over six years of pre-clinical in vitro and in vivo testing led to the development of Exebryl-1(R) that is believed to prevent beta-amyloid protein formation, deposition, and accumulation at all stages of the disease progression. In addition, Exebryl-1(R) also contributes to a reduction and clearance of beta-amyloid protein deposits already existing in the brain as shown by a significant and marked reduction in brain amyloid plaques in older Alzheimer's transgenic animals.

Initial studies suggest that Exebryl-1(R) may also have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The presence of neurofibrillary tangles in brain containing tau prote
'/>"/>

SOURCE ProteoTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  The Alabama Supreme Court, in ... can sue drug makers who mislead doctors into believing that ... The case is Weeks v. Wyeth, and the decision came ... that same case last year. Heninger Garrison Davis attorneys ... patient in the case, Danny Weeks . ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive ... medical device company, announced today that Mitsubishi Corporation ... and robotic visualization system in Japan ... sale in Japan in the ... also the exclusive distributor for Karl Storz GMBH & ...
(Date:8/19/2014)... Aug. 19, 2014  As power morcellator lawsuits ... Bernstein Liebhard LLP notes that women in need ... a number of options that do not involve ... According to a report published by The Wall ... options include a mini-laparotomy and vaginal hysterectomy. Non-surgical ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... , Jan. 25 Curemark, LLC , ( www.curemark.com ... neurological diseases, announced that the company is now enrolling patients in Phase ... the country.  The sites are: , Mount Sinai School of Medicine, ... University of Texas, Houston Indiana University, ...
... , MELVILLE, N.Y. , Jan. 25 ... the largest distributor of health care products and services to office-based ... Bradley T. Sheares , Ph.D. to the Company,s Board of Directors. ... a wealth of health care experience to the Henry Schein Board. ...
Cached Medicine Technology:Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 2Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 3Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 2Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 3Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 5
(Date:8/20/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief operating officer ... Ore. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... healthcare organization serving a population of more than 35,000 ...
(Date:8/20/2014)... Hope For The Warriors® is excited to announce ... in Washington, DC on Thursday, October 2, 2014 at ... the courage of our wounded service members, their families, ... Got Heart, Give Hope® Celebration will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Inc. ... year on its 33rd annual Inc. 500|5000, an ... The list represents the most comprehensive look at ... entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, ... names gained early exposure as members of the ...
(Date:8/20/2014)... Atlanta, GA (PRWEB) August 20, 2014 ... Data to healthcare, Jvion successfully predicted stage iii ... levels that, in some situations, approached 90%. A ... never been achieved in commercial or academic settings. ... and prevent all types of hospital-acquired conditions to ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo tickets for ... well-known medium has been thrilling many with her amazing ... cities, with tickets becoming available August 15. , Among ... Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, Houston, New ... Diego. The medium’s fans can obtain Theresa Caputo tour ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2
... treatment mainstay for prostate cancer puts men at increased ... large observational study published in the// Sept. 20 Journal ... have high five-year survival rates, but they also have ... study author Nancy Keating, MD, MPH, assistant professor of ...
... Chile announced a tax on airline tickets to raise ... who cannot afford them//. ,Representatives from the five ... Ignacio Lula da Silva of Brazil, were present for ... Annan and former US President Bill Clinton also attended. ...
... are almost twice as likely to attempt suicide as non-Maori ... than other New Zealanders. ,The survey conducted by the ... the prevalence of mental disorders among different ethnic groups in ... including 2600 Maori. ,It was found that thirty percent ...
... Recent studies have revealed that increased levels of ... events// in healthy women according to Boston-based investigators. ... screening of lipoprotein(a) in the population as a ... with cardiovascular risk. Besides that most lipid-correcting therapies ...
... tested as an anticancer agent to treat breast cancer, supports ... ,Duchene muscular dystrophy is a disease characterized by ... According to earlier studies, the functional decline of "dystrophic" ... fiber size. ,The recent study conducted by Dr. ...
... (China): More than 200 children were taken ill after eating ... ,The 223 students were admitted to a hospital and are ... ,Students of Dianshi Town High School began reporting symptoms ... at their school Monday and were immediately hopitalised. ...
Cached Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2Health News:Anti-cancer drug may treat muscular dystrophy 2
Inquire...
... brings you into the new age of ... offer your patients immediate, long-term results for ... This injectable filler offers superior versatility for ... reconstructive treatments. Long-lasting, Radiesse saves time and ...
... HEMOCHRON Response is a whole ... to be used at the ... easy-to-read screen and data management ... ID options. QC and operator ...
... Revitol Cellulite Cream is a revolutionary ... eliminating inches. Revitol Cellulite Removal Cream permits ... problem areas. With Revitol you can rid ... Just apply the Cellulite Cream to your ...
Medicine Products: